BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes. ✅
Go to Publication ✅
Glycobiology (Glycobiology ) Vol: 23 Issue 11 Pages: 1281-92 Pub: 2013 Nov Epub: 2013 Sep 7 Authors Yu ZT , Chen C , Newburg DS , |
|
|
Prebiotics Mediate Microbial Interactions in a Consortium of the Infant Gut Microbiome. ✅
International journal of molecular sciences (Int J Mol Sci ) Vol: 18 Issue 10 Pages: Pub: 2017 Oct 4 Epub: 2017 Oct 4 Authors Medina DA , Pinto F , Ovalle A , Thomson P , Garrido D , |
|
|
Consumption of human milk oligosaccharides by gut-related microbes. ✅
Go to Publication ✅
Journal of agricultural and food chemistry (J Agric Food Chem ) Vol: 58 Issue 9 Pages: 5334-40 Pub: 2010 May 12 Epub: Authors Marcobal A , Barboza M , Froehlich JW , Block DE , German JB , Lebrilla CB , Mills DA , |
|
|
Selective Utilization of the Human Milk Oligosaccharides 2`-Fucosyllactose, 3-Fucosyllactose, and Difucosyllactose by Various Probiotic and Pathogenic Bacteria. ✅
Go to Publication ✅
Journal of agricultural and food chemistry (J Agric Food Chem ) Vol: 69 Issue 1 Pages: 170-182 Pub: 2021 Jan 13 Epub: 2020 Dec 31 Authors Salli K , Hirvonen J , Siitonen J , Ahonen I , Anglenius H , Maukonen J , |
|
|
Immunomodulatory and Prebiotic Effects of 2`-Fucosyllactose in Suckling Rats. ✅
Go to Publication ✅
Frontiers in immunology (Front Immunol ) Vol: 10 Issue Pages: 1773 Pub: 2019 Epub: 2019 Jul 31 Authors Azagra-Boronat I , Massot-Cladera M , Mayneris-Perxachs J , Knipping K , Van`t Land B , Tims S , Stahl B , Garssen J , Franch À , Castell M , Rodríguez-Lagunas MJ , Pérez-Cano FJ , |
|
|
The Protective Effects of 2`-Fucosyllactose against E. Coli O157 Infection Are Mediated by the Regulation of Gut Microbiota and the Inhibition of Pathogen Adhesion. ✅
Nutrients (Nutrients ) Vol: 12 Issue 5 Pages: Pub: 2020 May 1 Epub: 2020 May 1 Authors Wang Y , Zou Y , Wang J , Ma H , Zhang B , Wang S , |
|
|
Screening competition and cross-feeding interactions during utilization of human milk oligosaccharides by gut microbes. ✅
Go to Publication ✅
Microbiome research reports (Microbiome Res Rep ) Vol: 3 Issue 1 Pages: 12 Pub: 2024 Epub: 2024 Jan 1 Authors Díaz R , Garrido D , |
|
|
2'-Fucosyllactose alleviates OVA-induced food allergy in mice by ameliorating intestinal microecology and regulating the imbalance of Th2/Th1 proportion. ✅
Go to Publication ✅
Food & function (Food Funct ) Vol: 14 Issue 24 Pages: 10924-10940 Pub: 2023 Dec 11 Epub: 2023 Dec 11 Authors Kou R , Wang J , Li A , Wang Y , Fan D , Zhang B , Fu W , Liu J , Fu H , Wang S , |
|
|
Modulating the developing gut microbiota with 2'-fucosyllactose and pooled human milk oligosaccharides. ✅
Go to Publication ✅
Microbiome (Microbiome ) Vol: 13 Issue 1 Pages: 44 Pub: 2025 Feb 7 Epub: 2025 Feb 7 Authors Renwick S , Furst A , Knip M , DIABIMMUNE Study Group , Bode L , Danska JS , Allen-Vercoe E , |
|
|
2'-Fucosyllactose ameliorates aging-related osteoporosis by restoring gut microbial and innate immune homeostasis. ✅
Journal of advanced research (J Adv Res ) Vol: Issue Pages: Pub: 2024 Nov 14 Epub: 2024 Nov 14 Authors Li A , Kou R , Wang J , Zhang B , Zhang Y , Liu J , Hu Y , Wang S , |
|
|
Human milk oligosaccharide 2'-fucosyllactose protects against high-fat diet-induced obesity by changing intestinal mucus production, composition and degradation linked to changes in gut microbiota and faecal proteome profiles in mice. ✅
Go to Publication ✅
Gut (Gut ) Vol: 73 Issue 10 Pages: 1632-1649 Pub: 2024 Sep 9 Epub: 2024 Sep 9 Authors Paone P , Latousakis D , Terrasi R , Vertommen D , Jian C , Borlandelli V , Suriano F , Johansson MEV , Puel A , Bouzin C , Delzenne NM , Salonen A , Juge N , Florea BI , Muccioli GG , Overkleeft H , Van Hul M , Cani PD , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
